Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ERAS
stocks logo

ERAS

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.095
-14.05%
--
--
-0.105
-4.55%
--
--
-0.105
-12.5%
Estimates Revision
Stock Price
Go Up
up Image
+98.14%
In Past 3 Month
Wall Street analysts forecast ERAS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ERAS is 4.50 USD with a low forecast of 1.00 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast ERAS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ERAS is 4.50 USD with a low forecast of 1.00 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
1 Sell
Moderate Buy
Current: 3.190
sliders
Low
1.00
Averages
4.50
High
6.00
Current: 3.190
sliders
Low
1.00
Averages
4.50
High
6.00
Guggenheim
Buy
maintain
$3 -> $5
2025-11-14
Reason
Guggenheim
Price Target
$3 -> $5
2025-11-14
maintain
Buy
Reason
Guggenheim raised the firm's price target on Erasca to $5 from $3 and keeps a Buy rating on the shares after the company reported Q3 results and provided a pipeline update. The firm's raised target reflects recent Phase 1 trial initiations, recent additional validation from peer programs, and likely increasing investor anticipation ahead of the first potential clinical data disclosures from both of the company's programs in 2025, the analyst noted.
Stifel
Buy
maintain
$4 -> $6
2025-11-06
Reason
Stifel
Price Target
$4 -> $6
2025-11-06
maintain
Buy
Reason
Stifel raised the firm's price target on Erasca (ERAS) to $6 from $4 and keeps a Buy rating on the shares. The firm notes the company announced issuance of composition of matter patent for lead pan-RAS program ERAS-0015. Stifel views this as a significant de-risking event. The firm notes that no large pharma company, to its knowledge, has brought forward a pan-RAS molecular glue even in the wake of Revolution Medicines' (RVMD) pan-RAS dominance.
Stifel
Laura Prendergast
initiated
$4
2025-10-15
Reason
Stifel
Laura Prendergast
Price Target
$4
2025-10-15
initiated
Reason
Stifel analyst Laura Prendergast initiated coverage of Erasca (ERAS) with a Buy rating and $4 price target. The firm highlights a valuation gap between Revolution Medicines' (RVMD) daraxonrasib and Erasca's ERAS-0015, telling investors that while the former's pan-RAS inhibitor is expected to have a substantial first-to-market advantage, it believes the extensive total addressable market "leaves plenty of room for a major second mover." The firm models ERAS-0015 to launch in the second half of 2030 and generate $1.56B in revenue by 2035, the analyst tells investors.
BofA
Buy
to
Underperform
downgrade
$4
2025-09-03
Reason
BofA
Price Target
$4
2025-09-03
downgrade
Buy
to
Underperform
Reason
BofA downgraded Erasca to Underperform from Buy with a price target of $1.50, down from $4.
BofA
Buy -> Underperform
downgrade
$4 -> $1
2025-09-03
Reason
BofA
Price Target
$4 -> $1
2025-09-03
downgrade
Buy -> Underperform
Reason
As previously reported, BofA double downgraded Erasca to Underperform from Buy with a price target of $1, down from $4, as the firm sees "an increasingly high bar to clear" to prove clinical differentiation in the ever-growing molecular glue landscape for solid tumors for lead molecular glue drugs ERAS-0015 and ERAS-4001. The firm also sees "a huge amount of spend and time required" to evaluate combination options and earlier lines of therapy, which are likely to be the largest value unlock for both drugs, the analyst added. In addition, the firm views it as unlikely that Erasca's melanoma drug naporafenib finds a partner.
Morgan Stanley
Overweight -> Equal Weight
downgrade
$4 -> $2
2025-08-17
Reason
Morgan Stanley
Price Target
$4 -> $2
2025-08-17
downgrade
Overweight -> Equal Weight
Reason
Morgan Stanley downgraded Erasca to Equal Weight from Overweight with a price target of $2, down from $4. The firm sees better opportunities in the space after Erasca announced its fifth reprioritization with plans to seek a strategic partner to further develop naporafenib. The company is not expected to report initial clinical data until 2026, the analyst tells investors in a research note.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Erasca Inc (ERAS.O) is -7.33, compared to its 5-year average forward P/E of -4.79. For a more detailed relative valuation and DCF analysis to assess Erasca Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-4.79
Current PE
-7.33
Overvalued PE
-2.35
Undervalued PE
-7.23

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-2.77
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.94
Undervalued EV/EBITDA
-6.48

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

ERAS News & Events

Events Timeline

(ET)
2025-11-12
16:13:07
Erasca Announces Q3 Earnings Per Share of 11 Cents, Exceeding Consensus Estimate of 10 Cents
select
2025-11-06 (ET)
2025-11-06
08:37:11
Erasca reveals the granting of a U.S. patent for ERAS-0015
select
2025-08-12 (ET)
2025-08-12
16:08:14
Erasca reports Q2 EPS (12c), consensus (12c)
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
2.0
12-03Benzinga
Major Stocks Including Gitlab, Acadia Healthcare, and Box Decline in Wednesday's Pre-Market Trading

  • U.S. Stock Futures: U.S. stock futures are up, with Dow futures increasing by approximately 0.1% on Wednesday morning.

  • GitLab's Financial Results: GitLab Inc. shares fell 8% in pre-market trading after reporting third-quarter earnings that beat estimates but provided fourth-quarter sales guidance below expectations.

  • Other Stocks Declining: Acadia Healthcare Company saw a significant drop of 22.7% after cutting its full-year guidance, while other companies like Pure Storage and Box also experienced declines in pre-market trading.

  • CrowdStrike's Performance: Despite a slight decline in pre-market trading, CrowdStrike Holdings reported better-than-expected financial results and raised its full-year guidance.

[object Object]
Preview
9.0
11-19Globenewswire
Targeted Cancer Treatments Accelerate as Precision Medicine Market Exceeds $106 Billion

  • Precision Oncology Market Growth: The precision oncology sector is rapidly evolving, with the market reaching $106.21 billion in 2025 and projected to grow to $158.9 billion by 2029, driven by advancements in biomarker-driven therapies and immunotherapy modalities.

  • Oncolytics Biotech's Pivotal Trial: Oncolytics Biotech has received FDA alignment for its Phase 3 study of pelareorep in pancreatic cancer, aiming to provide the first immunotherapy option for this indication, with promising preliminary data showing significant response rates.

  • ALX Oncology's Clinical Success: ALX Oncology reported a 65% objective response rate for its candidate evorpacept in treating high CD47-expressing HER2-positive gastric cancer, significantly outperforming standard therapies and guiding future clinical strategies.

  • Innovations from Other Biotech Firms: Companies like Erasca, Immuneering, and Prelude Therapeutics are advancing their respective therapies and programs, with notable achievements in patent protections and promising clinical trial results, indicating a strong pipeline in the oncology sector.

[object Object]
Preview
3.0
10-24NASDAQ.COM
Will Reduced Patient Days Impact Tenet Healthcare's Q3 Earnings?

  • Tenet Healthcare Earnings Report: Tenet Healthcare Corporation is set to report its third-quarter 2025 results on October 28, with earnings estimated at $3.33 per share and revenues of $5.24 billion, reflecting a year-over-year earnings increase of 13.7%.

  • Revenue and Admission Estimates: The full-year revenue estimate for 2025 is $21.16 billion, indicating a 2.4% rise year-over-year, while adjusted patient admissions are expected to grow by 2.7%, although a decrease of 5.7% is projected for same-hospital admissions.

  • Earnings Beat Uncertainty: Despite Tenet's history of beating earnings estimates, the current model suggests uncertainty for this quarter, with an Earnings ESP of 0.00% and a Zacks Rank of #4 (Sell), indicating a lower likelihood of an earnings beat.

  • Alternative Investment Opportunities: Other companies in the medical sector, such as Select Medical Holdings and Erasca, show more favorable conditions for potential earnings beats, with positive Earnings ESPs and strong Zacks Ranks.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Erasca Inc (ERAS) stock price today?

The current price of ERAS is 3.19 USD — it has decreased -3.04 % in the last trading day.

arrow icon

What is Erasca Inc (ERAS)'s business?

Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.

arrow icon

What is the price predicton of ERAS Stock?

Wall Street analysts forecast ERAS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ERAS is 4.50 USD with a low forecast of 1.00 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Erasca Inc (ERAS)'s revenue for the last quarter?

Erasca Inc revenue for the last quarter amounts to -32.55M USD, decreased -12.61 % YoY.

arrow icon

What is Erasca Inc (ERAS)'s earnings per share (EPS) for the last quarter?

Erasca Inc. EPS for the last quarter amounts to -21664000.00 USD, decreased -3.39 % YoY.

arrow icon

What changes have occurred in the market's expectations for Erasca Inc (ERAS)'s fundamentals?

The market is revising No Change the revenue expectations for ERAS for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 98.14%.
arrow icon

How many employees does Erasca Inc (ERAS). have?

Erasca Inc (ERAS) has 103 emplpoyees as of December 05 2025.

arrow icon

What is Erasca Inc (ERAS) market cap?

Today ERAS has the market capitalization of 905.04M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free